Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases

OBJECTIVE: Denosumab, an anti-RANKL monoclonal antibody, was reported to improve bone mineral density (BMD) and reduce fracture risk, offering favorable efficacy against postmenopausal osteoporosis. However, some patients have experienced a reduced BMD despite denosumab therapy. METHODS: We performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Kaichi, Shikano, Kotaro, Kawazoe, Mai, Kawai, Shinichi, Nanki, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449617/
https://www.ncbi.nlm.nih.gov/pubmed/35965073
http://dx.doi.org/10.2169/internalmedicine.8560-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449617/
https://www.ncbi.nlm.nih.gov/pubmed/35965073
http://dx.doi.org/10.2169/internalmedicine.8560-21

Ejemplares similares